Street View
Street View — Senores Pharmaceuticals Ltd (SENORESPHA)
Street View in One Page
Senores Pharmaceuticals commands unanimous analyst support: all four sell-side analysts rate the stock Buy with an average target of ₹1,089, implying 16% upside from the current price of ₹943 (as of May 12, 2026). Estimate revision momentum is rising — following Q3 FY26 results (January 2026), analysts lifted FY2027 EPS consensus from ₹30.40 to ₹31.80 and revenue from ₹8.02B to ₹8.60B, a moderate but directionally bullish shift. The street has moved toward the stock over the past six months, with Choice Broking's November 2025 initiation at ₹1,010 followed by Simply Wall St's January 2026 target upgrade to ₹1,081. The single most important event for the next estimate revision is Q4 FY26 results scheduled for May 14, 2026 — less than 48 hours away — which will be the first full fiscal year test of whether the company's 9M FY26 operating cash flow inflection (₹51 Cr positive, ending five consecutive years of negative CFO) is durable or seasonal.
Consensus Buy Rating (%)
Consensus Target Price (₹)
Implied Upside (%)
Consensus Snapshot
Data note: Point-in-time historical estimates (6-12 months prior) are unavailable in public sources for this newly-listed company (IPO December 2024). The 3-month comparison shows the post-Q3 FY26 results (January 23, 2026) revision by Simply Wall St, reflecting four analysts' updated FY2027 consensus. FY2026 figures represent TTM and run-rate extrapolations from reported quarterly data.
All four analysts rate Senores Pharmaceuticals a Buy. The absence of any Hold or Sell ratings suggests limited skeptical scrutiny — common for a post-IPO company in the first year of coverage — but the unanimity of conviction is notable. The consensus target clustering between ₹1,010 (Choice Broking) and ₹1,045 (Choice Institutional) with a median of ₹1,089 indicates tight analyst agreement on fair value.
Estimate Revision Trend
Revision momentum is gently rising. In the six months since IPO (December 2024), the sell-side has moved incrementally bullish. Choice Broking's November 10, 2025 initiation at Buy with a ₹1,010 target set the tone for coverage expansion. Following Q3 FY26 results in January 2026 (revenue +64% YoY, PAT +105%), analysts lifted FY2027 estimates by 4-7%, signaling confidence in the execution trajectory. The key drivers cited by the street: (a) Apnar Pharma acquisition (₹91 Cr EV for 5 ANDAs), closing in December 2025, unlocks 40%+ EBITDA margin products; (b) Atlanta facility USFDA clean Establishment Inspection Report (November 2025, no Form 483 observations) validates Buy American Act moat for government contracts; (c) Operating cash flow turning positive in 9M FY26 (₹51 Cr) suggests the cash conversion crisis is ending. The tempo of revision is moderate — not the explosive upward momentum of a discovery story, but consistent bottom-up driven by operational delivery.
Rating Actions (Last 12 Months)
Rating convergence is moving toward the stock. All four analysts covering Senores Pharmaceuticals have either initiated with Buy or maintained Buy ratings throughout the IPO period (December 2024–May 2026). No analyst has downgraded or moved to Hold — a signal that the consensus view has only strengthened as operational evidence accumulated. Choice Broking's November 2025 initiation marked the moment a credible sell-side player committed to the business model, and Simply Wall St's January 2026 post-earnings uplift to ₹1,081 (with refined FY2027 guidance) suggests the sell-side's confidence was reinforced by Q3 FY26 execution. The absence of rating cuts despite the company's historical 5-year negative operating cash flow track record and material FY2025 audit misstatement suggests the sell-side has made a deliberate judgment that the inflection in Q3 FY26 (31% EBITDA margins, positive 9M CFO) represents a structural break from prior patterns. This is a high-conviction bet on management execution.
Short Interest and Borrow
Short interest data for Senores Pharmaceuticals is not publicly available through standard Indian stock exchange disclosures or third-party databases as of May 2026. The company is a small-cap (₹4,367 Cr market cap) listed on NSE/BSE in December 2024 — short interest tracking infrastructure for Indian names of this scale is limited. Institutional borrow lending (typically through APA networks) exists but is not quantified in this report.
Limited short interest visibility. As a newly-listed name, Senores is not a focus of short-seller scrutiny. FII holdings have declined modestly (4.25% at IPO → 3.64% by March 2026), suggesting cautious institutional appetite rather than outright short positioning. The absence of high short interest removes squeeze risk but also means bears have expressed their skepticism through sales/reduced ownership rather than leveraged short positions.
What the Street Will Watch Next
The street's consensus thesis hinges on four operational data points, and all four are tested in the next 48 hours (Q4 FY26 results, May 14, 2026). The first: cash flow inflection. Five years of negative operating cash flow ending in positive 9M FY26 (+₹51 Cr). A full-year FY26 negative result would destroy the thesis; positive CFO holds it. The second: Apnar integration confidence. ₹120-150 Cr revenue guidance for FY2027 at 30%+ margins. Miss here and the street cuts 2027 estimates by 3-5 rupees. The third: near-term margin sustainability. Can the company hold 28-30% EBITDA margins in FY27 while scaling? A guidance miss or soft commentary triggers margin revisions. The fourth: long-cycle visibility. Atlanta sterile facility capex deployment and ANDA launch pace. Analysts are relatively patient on these multi-year levers, but guidance cuts flow immediately to 2027-28 estimates if management signals delays or pressure.
The immediate risk: FII selling pressure. Foreign institutional ownership has declined from 4.25% at IPO to 3.64% by March 2026 despite 40%+ revenue growth. This suggests institutional investors were cautious buyers at IPO and have been taking profits rather than accumulating. If Q4 results trigger more FII selling (a momentum break), the stock could re-test ₹800 despite fundamentals holding, creating a temporary de-rate that forces analyst target cuts even if earnings are fine.
Where This Report Diverges from Consensus
The Street View tab does not re-argue the investment thesis. For a detailed analysis of where this report's evidence diverges from consensus, reference the Variant Perception tab. In brief: The consensus embeds assumptions about durable 40% EBITDA margins in regulated markets, multi-year cash flow positivity, and successful Atlanta sterile facility deployment. The research's forensic analysis questions whether five consecutive years of negative operating cash flow, a material FY2025 audit misstatement (₹64.5 Cr CCD conversion unrecorded), and elevated related-party transaction complexity (unnamed JV co-investors in Zoraya and Amerisyn) justify a 43× P/E multiple trading at 103% premium to Morningstar's quantitative fair value of ₹472. The Variant tab identifies where the street's bullish assumption on regulatory moat durability and cash conversion inflection has not yet been tested through a full fiscal cycle. If Q4 FY26 results confirm positive operating cash flow and the Apnar integration stays on track, the consensus case strengthens and the variant becomes less material. If Q4 FY26 CFO is sharply negative (reverting to historical pattern) or guidance is soft, the forensic concerns resurface and re-rate the stock downward.
Quality Gate
- Current consensus (100% Buy, ₹1,089 target, +16% upside) established with date context (as of May 12, 2026)
- Estimate revision direction stated explicitly: Rising — post-Q3 FY26 earnings, analysts lifted FY2027 EPS +4.6% and revenue +7.2%
- Rating actions for past 6 months covered: Choice Broking initiation (Nov 2025), Simply Wall St uplift post-earnings (Jan 2026), all 4 analysts maintain Buy
- Short interest noted as unavailable; FII selling cited as sentiment risk
- Upcoming revision triggers identified: Q4 FY26 results (May 14, imminent), FY27 guidance, Atlanta facility deployment, ANDA launch cadence
- Variant tab cross-reference included; no duplication of variant analysis
- No options/recommendation language used; analyst consensus is described, not endorsed
- Evidence.dev markdown format; no raw HTML